Evaluating Intervention Points in the Complement Cascade to Achieve & Improve Efficacy & Advance the Next Generation of Inhibitors for Inflammatory Diseases

10-12 December, 2024 | Boston, MA

Welcome to the 8th Annual Complement-Based Drug Development Summit

Achieving Efficacy & Exploring Indication Expansion for Complement Inhibitors

The complement community is shifting gear, with more companies than ever targeting alternative complement proteins for their therapies, allowing for a larger range of diseases to be targeted. 

With more assets in ophthalmology, neurology, and oncology than ever before, the complement-based therapeutics field has everyone asking the same question:  which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies? 

From the discovery of new pathways to target to post-approval indication expansion, the immunology landscape is primed to capitalize on the huge strides being taken in achieving efficacy and approving the safety profile of complement-based therapeutics.  

Join 100+ complement industry leaders, scientists, and clinicians at the premier, end-to-end 8th Complement-Based Drug Development Summit to shape the future of complement-targeted therapies.

Screenshot 2024-09-09 092624

Our World-Class Speaker Faculty Includes:

Previously Attending Companies Include:

MicrosoftTeams-image (1)

Top Testimonial:

Copy of 6th Cell Partner Logos (2) 1

 I learned a lot from this meeting from complement therapeutic point of view. I got some new ideas and industry collaborators to design and develop new drugs in the area of complement.

Our Partners:

Hycult Biotech, 8th Complement Based Drug Development Summit
National Jewish Health, 8th Complement Based Drug Development Summit
Quidel Corp, 8th Complement Based Drug Development Summit
Svar, 8th Complement Based Drug Development Summit

Other Events in the Series: